TC-99M SESTAMIBI AND OTHER AGENTS IN THE DETECTION OF METASTATIC MEDULLARY CARCINOMA OF THE THYROID

Authors
LEBOUTHILLIER G MORAIS J PICARD M PICARD D CHARTRAND R DAMOUR P
Citation
G. Lebouthillier et al., TC-99M SESTAMIBI AND OTHER AGENTS IN THE DETECTION OF METASTATIC MEDULLARY CARCINOMA OF THE THYROID, Clinical nuclear medicine, 18(8), 1993, pp. 657-661
Citations number
11
Categorie Soggetti
Radiology,Nuclear Medicine & Medical Imaging
Journal title
Clinical nuclear medicine → ACNP
ISSN journal
03639762
Volume
18
Issue
8
Year of publication
1993
Pages
657 - 661
Database
ISI
SICI code
0363-9762(1993)18:8<657:TSAOAI>2.0.ZU;2-5
Abstract
The 10-year survival rate for medullary carcinoma of the thyroid (MCT) is 50%; thus, good tumor-seeking radiopharmaceuticals are needed to l ocalize foci of recurrence and metastasis during follow-up. Two patien ts with metastatic MCT were studied with Tl-201, I-131 MIBG, Tc-99m (V )-DMSA, and Tc-99m MIBI. A SPECT study with the latter agent allowed t he visualization and precise localization of a metastatic mediastinal lymph node. More studies need to be done to evaluate the role of Tc-99 m MIBI in the detection of recurrence and metastases of MCT.